Cabaletta Bio, Inc.

CABA

US12674W1099

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 20:59:47 04/06/2024 BST			5-day change	1st Jan Change
9.935 ^USD	-0.75%		-6.89%	-56.23%

05-15	Cabaletta Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
03-22	HC Wainwright Adjusts Cabaletta Bio's Price Target to $30 From $25, Maintains Buy Rating	MT

Cabaletta Bio, Inc. Appoints Michael Gerard as General Counsel

September 07, 2021 at 01:00 pm

Cabaletta Bio, Inc. announced that Michael Gerard has been appointed general counsel. Mr. Gerard most recently served as Associate General Counsel at Spark Therapeutics.

Latest news about Cabaletta Bio, Inc.

Cabaletta Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-15	CI
HC Wainwright Adjusts Cabaletta Bio's Price Target to $30 From $25, Maintains Buy Rating	03-22	MT
Cabaletta Bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-21	CI
Cabaletta Bio, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	03-21	CI
Cabaletta Bio Gets Orphan Drug Designation From FDA For Systemic Sclerosis Treatment	03-20	MT
North American Morning Briefing : Markets on Hold -2-	03-20	DJ
North American Morning Briefing : Stock Futures -2-	03-13	DJ
Jefferies Initiates Cabaletta Bio with Buy Rating, $36 Price Target	02-05	MT
Cabaletta Bio Secures Orphan Drug Designation for Myositis Treatment	02-02	MT
Cabaletta Bio Gets Orphan Drug Designation for Potential Autoimmune Disease Treatment	02-01	DJ
Cabaletta, Inc. Announces FDA Grants Orphan Drug Designation to CABA-201	02-01	CI
Transcript : Cabaletta Bio, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-09-2024 05:15 PM	01-10
Cabaletta Bio Gets Additional FDA Fast Track Labels For CABA-201	01-08	MT
Cabaletta Bio, Inc. Receives Additional FDA Fast Track Designations for CABA-201 in Dermatomyositis and Systemic Sclerosis	01-08	CI
Cabaletta Bio, Inc.(NasdaqGS:CABA) added to NASDAQ Biotechnology Index	12-18	CI
Morgan Stanley Cuts Price Target on Cabaletta Bio to $25 From $28 as FDA Probes T-Cell Malignancies in CAR-T Cell Therapy, Keeps Overweight Rating	11-29	MT
Health Care Down as FDA Probes Immunotherapy Treatments -- Health Care Roundup	11-28	DJ
Sector Update: Health Care Stocks Retreat in Late Afternoon	11-28	MT
Sector Update: Health Care	11-28	MT
Cabaletta Bio Down as FDA Looks Into Issues With Several Companies' Approved CAR T Drugs	11-28	DJ
FDA Probes T-Cell Malignancies in Patients Receiving CAR-T Cell Therapies	11-28	MT
Cantor Fitzgerald Adjusts Price Target on Cabaletta Bio to $50 From $40, Maintains Overweight Rating	11-15	MT
North American Morning Briefing : Stocks Seen -2-	11-15	DJ
HC Wainwright Adjusts Price Target on Cabaletta Bio to $25 From $17, Keeps Buy Rating	11-10	MT
Cabaletta Bio, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-09	CI

Cabaletta Bio, Inc. is a clinical-stage biotechnology company. The Company is focused on the discovery and development of engineered T cell therapies that have the potential to provide deep and durable, perhaps curative, responses with one-time administration for patients with autoimmune diseases. Its Cabaletta Approach to B cell Ablation (CABA) platform encompasses two strategies: Chimeric Antigen Receptor T cells for Autoimmunity (CARTA) and Chimeric AutoAntibody Receptor T cells (CAART). CABA-201, its lead product candidate from its CARTA platform, is a 4-1BB co-stimulatory domain-containing fully human CD19-CAR T construct designed to treat patients with a range of autoimmune diseases. Its DSG3-CAART product candidate is being evaluated for the treatment of mPV, a subtype of PV that affects the epithelium of the mucous membranes, in the Phase 1 DesCAARTes TM trial. Its MuSK-CAART product candidate is designed to treat a subset of patients with MG, targeting autoreactive B cells.

Sector

Biotechnology & Medical Research

Calendar

04:00pm - Jefferies Global Healthcare Conference

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

9.94 USD

Average target price

33.56 USD

Spread / Average Target

+237.58%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
CABALETTA BIO, INC.	-56.23%	480M
VERTEX PHARMACEUTICALS INCORPORATED	+16.73%	123B
REGENERON PHARMACEUTICALS, INC.	+13.04%	107B
BIONTECH SE	-5.80%	24.01B
ARGENX SE	+2.62%	22.59B
GENMAB A/S	-10.09%	18.16B
WUXI APPTEC CO., LTD.	-40.52%	16.84B
BEIGENE, LTD.	-14.00%	16.23B
NEUROCRINE BIOSCIENCES, INC.	+1.18%	13.43B
SAREPTA THERAPEUTICS, INC.	+24.18%	11.32B

Bio Therapeutic Drugs